Julia E Inglis1, Michelle C Janelsins2, Eva Culakova2, Karen M Mustian2, Po-Ju Lin2, Ian R Kleckner2, Luke J Peppone2. 1. Department of Surgery, University of Rochester Medical Center (URMC), 265 Crittenden Blvd, CU 420658, Rochester, NY, 14642, USA. Julia_Inglis@URMC.Rochester.edu. 2. Department of Surgery, University of Rochester Medical Center (URMC), 265 Crittenden Blvd, CU 420658, Rochester, NY, 14642, USA.
Abstract
PURPOSE: To assess the impact of obesity on cancer-related fatigue (CRF) in patients with breast cancer, through a secondary analysis of a large, longitudinal, nationwide study of breast cancer patients beginning chemotherapy. METHODS: All patients (N = 565; aged 53 ± 10.6) with breast cancer completed the multidimensional fatigue symptom inventory and the symptom inventory to measure CRF symptoms at baseline, post-chemotherapy, and 6 months post-chemotherapy. Height and weight at baseline were used to categorize subjects based on body mass index (BMI): obese (≥ 30.0 kg/m2; n = 294), overweight (25.0-29.9 kg/m2; n = 146), and normal weight (18.5-24.9 kg/m2; n = 125). Multivariate regression models evaluated the relationship of obesity level to CRF over time, controlling for age, menopausal status, race, Karnofsky Performance Status, cancer stage, radiation, and exercise status. RESULTS: At baseline, the obese had significantly higher CRF symptoms than the normal weight subjects for both the Multidimensional fatigue symptom inventory (MFSI) total (obese = 11.2 vs normal weight = 6.3; p = 0.03) and Symptom Inventory (SI) (obese = 3.5 vs normal weight = 2.9; p = 0.03). Significantly higher SI fatigue scores persisted at post-chemotherapy for the obese (obese = 5.0 vs normal weight = 4.4; p = 0.02). At 6 months post-chemotherapy, the obese patients still had significantly higher SI fatigue scores (obese = 3.5 vs normal weight = 3.0; p = 0.05). CONCLUSION: Obese patients suffered greater CRF from pre-chemotherapy through 6 months post-chemotherapy. Recommendations for weight loss or weight maintenance may impact CRF levels in obese breast cancer patients before and after chemotherapy.
PURPOSE: To assess the impact of obesity on cancer-related fatigue (CRF) in patients with breast cancer, through a secondary analysis of a large, longitudinal, nationwide study of breast cancerpatients beginning chemotherapy. METHODS: All patients (N = 565; aged 53 ± 10.6) with breast cancer completed the multidimensional fatigue symptom inventory and the symptom inventory to measure CRF symptoms at baseline, post-chemotherapy, and 6 months post-chemotherapy. Height and weight at baseline were used to categorize subjects based on body mass index (BMI): obese (≥ 30.0 kg/m2; n = 294), overweight (25.0-29.9 kg/m2; n = 146), and normal weight (18.5-24.9 kg/m2; n = 125). Multivariate regression models evaluated the relationship of obesity level to CRF over time, controlling for age, menopausal status, race, Karnofsky Performance Status, cancer stage, radiation, and exercise status. RESULTS: At baseline, the obese had significantly higher CRF symptoms than the normal weight subjects for both the Multidimensional fatigue symptom inventory (MFSI) total (obese = 11.2 vs normal weight = 6.3; p = 0.03) and Symptom Inventory (SI) (obese = 3.5 vs normal weight = 2.9; p = 0.03). Significantly higher SI fatigue scores persisted at post-chemotherapy for the obese (obese = 5.0 vs normal weight = 4.4; p = 0.02). At 6 months post-chemotherapy, the obesepatients still had significantly higher SI fatigue scores (obese = 3.5 vs normal weight = 3.0; p = 0.05). CONCLUSION:Obesepatients suffered greater CRF from pre-chemotherapy through 6 months post-chemotherapy. Recommendations for weight loss or weight maintenance may impact CRF levels in obese breast cancerpatients before and after chemotherapy.
Entities:
Keywords:
Breast cancer; Cancer-related fatigue; Chemotherapy; Obesity
Authors: P J Goodwin; M Ennis; K I Pritchard; D McCready; J Koo; S Sidlofsky; M Trudeau; N Hood; S Redwood Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: Irene Cantarero-Villanueva; Noelia Galiano-Castillo; Carolina Fernández-Lao; Lourdes Diaz-Rodríguez; Antonio Manuel Fernández-Pérez; María J Sánchez; Manuel Arroyo-Morales Journal: Clin Breast Cancer Date: 2014-11-20 Impact factor: 3.225
Authors: Angela A F Gravena; Sheila C R Brischiliari; Tiara C R Lopes; Cátia M D Agnolo; Maria D B Carvalho; Sandra M Pelloso Journal: BMC Womens Health Date: 2013-11-14 Impact factor: 2.809
Authors: R Nagrani; S Mhatre; P Rajaraman; I Soerjomataram; P Boffetta; S Gupta; V Parmar; R Badwe; R Dikshit Journal: Eur J Cancer Date: 2016-08-27 Impact factor: 9.162
Authors: Basil S Karam; Alejandro Chavez-Moreno; Wonjoon Koh; Joseph G Akar; Fadi G Akar Journal: Cardiovasc Diabetol Date: 2017-09-29 Impact factor: 9.951
Authors: Chad W Wagoner; Jordan T Lee; Erik D Hanson; Zachary Y Kerr; Kirsten A Nyrop; Hyman B Muss; Claudio L Battaglini Journal: Breast Cancer Date: 2022-06-24 Impact factor: 3.307
Authors: Amber S Kleckner; Edwin van Wijngaarden; Todd A Jusko; Ian R Kleckner; Po-Ju Lin; Karen M Mustian; Luke J Peppone Journal: Cancer Res Commun Date: 2022-03-31
Authors: AnnaLynn M Williams; Carly Paterson Khan; Charles E Heckler; Debra L Barton; Mary Ontko; Jodi Geer; Amber S Kleckner; Shaker Dakhil; Jerry Mitchell; Karen M Mustian; Luke J Peppone; Victor Kipnis; Charles S Kamen; Ann M O'Mara; Michelle C Janelsins Journal: Breast Cancer Res Treat Date: 2021-01-04 Impact factor: 4.872
Authors: Fares Mohammed Saeed Muthanna; Mahmathi Karuppannan; Bassam Abdul Rasool Hassan; Ali Haider Mohammed Journal: Osong Public Health Res Perspect Date: 2021-04-29
Authors: Antonio Di Meglio; Elise Martin; Tracy E Crane; Cecile Charles; Aude Barbier; Bruno Raynard; Anthony Mangin; Olivier Tredan; Carole Bouleuc; Paul H Cottu; Laurence Vanlemmens; Carine Segura-Djezzar; Anne Lesur; Barbara Pistilli; Florence Joly; Thomas Ginsbourger; Bernadette Coquet; Iris Pauporte; Guillemette Jacob; Aude Sirven; Julia Bonastre; Jennifer A Ligibel; Stefan Michiels; Ines Vaz-Luis Journal: Trials Date: 2022-03-04 Impact factor: 2.279
Authors: Julia E Inglis; Amber S Kleckner; Po-Ju Lin; Nikesha J Gilmore; Eva Culakova; Amy C VanderWoude; Karen M Mustian; I Diana Fernandez; Richard F Dunne; Jeremy Deutsch; Luke J Peppone Journal: Nutr Cancer Date: 2020-08-19 Impact factor: 2.900